The objectives of this study were to describe a potentially underappreciated pathology for post-traumatic persistent intractable dizziness and third window syndrome as well as the methods to diagnose and surgically manage this disorder.
Vertidiag is said to have developed a technical platform to induce controlled vestibular disorders and to measure their functional impacts. This platform uses behavioral pharmacology, along with a battery of cellular and molecular biology tools that support the understanding of the mechanisms of action of potential drug candidates.
Dr Kim Cavitt voices concerns about ideas in a November Hearing Review article that she says could be problematic for hearing care professionals relative to insurers, scope of practice, and medical costs. The authors, Drs Robert Traynor and Jay Hall, respond.